Skip to main content

1 Result(s)

within Buse Eglenen-Polat Remove this filter

and

  1. Article

    Open Access

    A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer

    There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a th...

    Buse Eglenen-Polat, Ryan R. Kowash, Hai-Cheng Huang, Silvia Siteni… in Nature Communications (2024)

    Download PDF (5735 KB) View Article